← FDA DRUG APPROVALS

FDA ANDA · ANDA209504

FENOFIBRATE

Sponsor: ANI PHARMS

APPLICATION
ANDA209504
TYPE
ANDA
ORIGINAL APPROVAL
2018-04-30
LATEST ACTION
2022-05-25
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

FENOFIBRATE (MICRONIZED)Prescription
FENOFIBRATE 200MG · CAPSULE · ORAL
FENOFIBRATE (MICRONIZED)Prescription
FENOFIBRATE 67MG · CAPSULE · ORAL
FENOFIBRATE (MICRONIZED)Prescription
FENOFIBRATE 134MG · CAPSULE · ORAL

Approval history

2022-05-25Labeling · Supplement 10 · standardAP
2019-05-15Labeling · Supplement 4 · standardAP
2019-05-13Labeling · Supplement 2 · standardAP
2018-04-30UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →